Polynovo Ltd PNV

Morningstar Rating
A$2.43 −0.09 (3.57%)
View Full Chart

Company Report

Polynovo Shares Appear Expensive Despite Maiden Profit

Polynovo’s strategy revolves around expanding its geographical footprint to increase access to its products and open new hospital accounts. With its geographical reach the firm estimates its products are available to 800 million people as of fiscal 2023, but highlights the global market is underserved. The firm entered several new markets in fiscal 2023 including India, France, Spain, Canada, and Hong Kong, Polynovo intends to enter more geographies with new regulatory approvals, particularly with a focus on China and Japan through distribution partners. While the US market is key for Polynovo, representing roughly 80% of sales in fiscal 2023, new geographies would diversify the sales mix.

Price vs Fair Value

PNV is trading at a 572% premium.
Price
A$2.43
Fair Value
A$7.70
Uncertainty
Very High
1-Star Price
A$9.68
5-Star Price
A$7.69
Economic Moat
Fpjdg
Capital Allocation
Hhcwdssw

Bulls Say, Bears Say

Bulls

NovoSorb BTM is a sound alternative treatment option for dermal regeneration given it is synthetic, and its ease of use and clinical performance.

Bears

Polynovo is still burning cash and there is very high uncertainty on the success and timing of entering new geographies or potential new indications for NovoSorb.

Trading Information

Previous Close Price
A$2.52
Day Range
A$2.432.50
52-Week Range
A$1.102.78
Bid/Ask
A$2.43 / A$2.47
Market Cap
A$1.68 Bil
Volume/Avg
940,023 / 1.6 Mil

Key Statistics

Price/Earnings (Normalized)
199.41
Price/Sales
16.52
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Growth
Total Number of Employees
8

Competitors

Valuation

Metric
PNV
NAN
FPH
Price/Earnings (Normalized)
199.4167.56100.31
Price/Book Value
23.265.9011.93
Price/Sales
16.526.3912.00
Price/Cash Flow
462.8648.9049.10
Price/Earnings
PNV
NAN
FPH

Financial Strength

Metric
PNV
NAN
FPH
Quick Ratio
2.875.250.88
Current Ratio
3.416.161.83
Interest Coverage
1.248.2513.77
Quick Ratio
PNV
NAN
FPH

Profitability

Metric
PNV
NAN
FPH
Return on Assets (Normalized)
6.37%6.94%11.54%
Return on Equity (Normalized)
9.21%9.11%15.07%
Return on Invested Capital (Normalized)
6.83%7.18%13.94%
Return on Assets
PNV
NAN
FPH

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
XsdhtmwfFbjbnk$196.0 Bil
Stryker Corp
SYK
ZsypgfjwfTmvj$133.8 Bil
Boston Scientific Corp
BSX
YpmrnkspFmmwlf$124.5 Bil
Medtronic PLC
MDT
YgjpbhgdQvwmx$113.2 Bil
Edwards Lifesciences Corp
EW
FmtbstxpvsMjhqtz$39.5 Bil
Koninklijke Philips NV ADR
PHG
FyfxTsypg$30.2 Bil
DexCom Inc
DXCM
WlpmwnqbGnzkw$27.3 Bil
Steris PLC
STE
YwtnlkbsBkkwp$22.8 Bil
Zimmer Biomet Holdings Inc
ZBH
CchtdtxrMrqh$21.3 Bil
Insulet Corp
PODD
ZdtjjjzbkzDdyprq$16.1 Bil

Sponsor Center